Biotech Values

[genisi]

Agree that the potential unique feature of clevudine will be a durable SVR after stopping therapy, which will be an unusual event in HBV with nucleoside therapy. However, the hint seen in earlier trial needs to be replicated in the phase 3 studies and I'm not convinced it will. So if it shows only modest benefit over Hepsera, in phase III trials, I think it still holds potential in combo if the combo prevents resistance, which is a key issue with monotherapy.

Btw, use of interferon in Europe is still high, due to the high rate of HBeAg seroconversion, and in part cause of guidelines.